# A Phase 1 Safety and PK Study of IV TP-271

> **NCT03234738** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 40 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** TP-271
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03234738
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2018-01-02
- **Final completion:** 2018-01-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234738, "A Phase 1 Safety and PK Study of IV TP-271". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03234738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*